טוען...
ACTR-38. SAFETY AND EFFECTIVENESS OF BEVACIZUMAB IN JAPANESE PATIENTS WITH MALIGNANT GLIOMA: POST-MARKETING SURVEILLANCE RESULTS
OBJECTIVES: In Japan, when bevacizumab was approved for malignant glioma patients in 2013, there were limited data on Japanese patients. In the global P3 AVAglio study, the incidence of cerebral hemorrhage, including tumor-related bleeding, and infections was higher in patients who received bevacizu...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692943/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.029 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|